Mutational analysis of the LMO4 gene, encoding a BRCA1‐interacting protein, in breast carcinomas

@article{Sutherland2003MutationalAO,
  title={Mutational analysis of the LMO4 gene, encoding a BRCA1‐interacting protein, in breast carcinomas},
  author={Kate D. Sutherland and Jane E. Visvader and David Y. H. Choong and Eleanor Y. M. Sum and Geoffrey J. Lindeman and Ian G. Campbell},
  journal={International Journal of Cancer},
  year={2003},
  volume={107}
}
The LIM domain‐only genes LMO1 and LMO2 are translocated in acute T cell leukemia (T‐ALL) and have been shown to be oncogenes in T lymphoid cells. LMO4, the fourth member of this family, is overexpressed in more than 50% of sporadic breast cancers, suggesting a role in breast oncogenesis. We recently found that LMO4 interacts with the breast/ovarian tumor suppressor BRCA1 and that LMO4 can repress its transcriptional activity. Since proto‐oncogene deregulation can result from activating… 
Genetic and Epigenetic Analysis of the Putative Tumor Suppressor km23 in Primary Ovarian, Breast, and Colorectal Cancers
TLDR
The data suggest that silencing of km23, either through somatic genetic mutation or promoter hypermethylation, is rare in ovarian, breast, and colorectal cancers.
LIM domain only 1: an oncogenic transcription cofactor contributing to the tumorigenesis of multiple cancer types
TLDR
The current findings on the role of LMO1 in tumorigenesis, the mechanisms of its oncogenic action, and the mechanisms that drive its aberrant activation in cancers are reviewed.
Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer
TLDR
There is no evidence that highly penetrant exonic or splice site mutations in FANCD2, BRIP1/BACH1, LMO4 or SFN contribute to familial breast cancer.
BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations
  • N. Karachaliou, C. Costa, +14 authors R. Rosell
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2013
TLDR
Baseline assessment of BRCA1 and LMO4 mRNA expression can help predict outcome to erlotinib, and low BRC a1 and high L MO4 levels were associated with longer PFS to erotinib.
Prognostic value of CtIP/RBBP8 expression in breast cancer
CtIP/RBBP8 is a multifunctional protein involved in transcription, DNA replication, DNA repair by homologous recombination and the G1 and G2 checkpoints. Its multiple roles are controlled by its
The LIM Domain Protein Lmo4 Is Highly Expressed in Proliferating Mouse Epithelial Tissues
TLDR
The expression profile of Lmo4 suggests that this cofactor is an important regulator of epithelial proliferation and has implications for its role in the pathogenicity of cancer.
LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
TLDR
It is found that LMO4 expression oscillates throughout the cell cycle with maximum expression occurring during G2/M and these changes precede oscillations in cullin-3 levels, which concludes that L MO4 is a novel cell cycle regulator with a key role in mediating ErbB2-induced proliferation, a hallmark of Erb B2-positive disease.
Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif
TLDR
The data suggest that most somatic nucleotide substitutions in human cancer may occur in sites that conform to the THEMIS motif, a novel motif identified within a WKVnRRRnVWK sequence.
LMO 4 is an essential mediator of ErbB 2 / HER 2 / Neu-induced breast cancer cell cycle progression
ErbB2/HER2/Neu-overexpressing breast cancers are characterized by poor survival due to high proliferation and metastasis rates and identifying downstream targets of ErbB2 should facilitate developing
Repression of Lim only protein 4-activated transcription inhibits proliferation and induces apoptosis of normal mammary epithelial cells and breast cancer cells
TLDR
The data indicate that LMO4 has similar cellular effects in normal mammary epithelial cells and breast cancer cells, and provide direct evidence for the idea that normal development and carcinogenesis share conserved molecular mechanisms.
...
1
2
...

References

SHOWING 1-10 OF 30 REFERENCES
The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer
TLDR
A role for LMO4 in maintaining proliferation of mammary epithelium is implied and deregulation of this gene may contribute to breast tumorigenesis, and the role of LIM-only transcriptional regulators in acute T cell leukemia is suggested.
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas
TLDR
Immunohistochemical staining of human breast specimens revealed BRCA1 nuclear foci in benign breast, invasive lobular cancers and low–grade ductal carcinomas, suggesting that absence of BRCa1 may contribute to the pathogenesis of a significant percentage of sporadic breast cancers.
The LIM Domain Protein LMO4 Interacts with the Cofactor CtIP and the Tumor Suppressor BRCA1 and Inhibits BRCA1 Activity*
TLDR
Findings reveal a novel complex between BRCA1, L MO4, and CtIP and indicate a role for LMO4 as a repressor of B RCA1 activity in breast tissue.
Characterization of a carboxy-terminal BRCA1 interacting protein
TLDR
Using the yeast two-hybrid and in vitro biochemical assays, it is shown that a protein, CtIP, interacts specifically with the carboxy-terminal segment of human BRCA1 from residues 1602–1863.
A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1.
TLDR
Extensive SSCP and sequence analysis of over 100 tumour and normal DNAs from familial and sporadic breast cancers and sporadic ovarian cancers failed to detect mutations in the coding region of this gene.
Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma
TLDR
The data point to a relationship between clinically relevant prognostic factors and specific genomic deletions in the BRCA1, BRCa2 and TP53 region, which is linked to high‐grade malignant tumors, to tumor size, and to loss of expression of the estrogen receptor.
Differential expression and mutation of the ras family genes in human breast cancer.
TLDR
The findings indicate that the aberrant expression of ras genes may be an initial event in breast cancer oncogenesis and that K-ras point mutations are rarely involved in the development of mammary neoplasias.
Binding of CtIP to the BRCT Repeats of BRCA1 Involved in the Transcription Regulation of p21 Is Disrupted Upon DNA Damage*
TLDR
It is suggested that the binding of the BRCT repeats of BRCA1 to CtIP/CtBP is critical in mediating transcriptional regulation of p21 in response to DNA damage.
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression
TLDR
It is suggested that BRCA1 may normally serve as a negative regulator of mammary epithelial cell growth whose function is compromised in breast cancer either by direct mutation or alterations in gene expression.
The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.
TLDR
Results show that Lmo2 is not needed for de novo capillary formation from mesoderm but is necessary for angiogenic remodeling of the existing capillary network into mature vasculature.
...
1
2
3
...